Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 9, 2010, Pages 1036-1041

  Herrlinger, K R ^a   Barthel, D N ^a   Schmidt, K J ^b   Buning J ^b   Barthel, C S ^a   Wehkamp, J ^a   Stange, E F ^a   Fellermann, K ^b  

^a ROBERT BOSCH HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; PREDNISOLONE; TACROLIMUS; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE COURSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FLUSHING; HERPES ZOSTER; HUMAN; HYPERSENSITIVITY REACTION; INFECTIOUS COMPLICATION; LOW DRUG DOSE; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROCTOCOLECTOMY; REMISSION; SIDE EFFECT; TREATMENT OUTCOME; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VIRUS PNEUMONIA; COLITIS, ULCERATIVE; DRUG RESISTANCE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77950575872     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04267.x     Document Type: Article

References (21)

1. Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006 55 (Suppl. 1 i16 35. (Pubitemid 43268291)
2. Faubion WA Jr., Loftus EV Jr., Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001 121 : 255 260. (Pubitemid 32729372)
3. Ho GT, Chiam P, Drummond H, et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 2006 24 : 319 330. (Pubitemid 43972900)
4. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994 330 : 1841 1845. (Pubitemid 24188135)
5. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004 10 : 73 8. (Pubitemid 38332164)
6. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 2005 17 : 79 84. (Pubitemid 40128931)
7. Carbonnel F, Boruchowicz A, Duclos B, et al. Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term responses. Dig Dis Sci 1996 41 : 2471 2476. (Pubitemid 27041805)
8. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002 8 : 317 324.
9. Yamamoto S, Nakase H, Mikami S, et al. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008 28 : 589 597.
10. Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998 93 : 1860 1866. (Pubitemid 29071695)
11. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006 55 : 1255 1262. (Pubitemid 44277355)
12. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005 128 : 1805 1811. (Pubitemid 40824691)
13. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005 353 : 2462 2476. (Pubitemid 41770166)
14. Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008 6 : 1112 1116.
15. Toruner M, Loftus EV Jr., Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008 134 : 929 936. (Pubitemid 351451967)
16. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006 4 : 1248 1254. (Pubitemid 44512213)
17. Hg SC, Kamm MA. Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis. Aliment Pharmacol Ther 2008 28 : 815 829.
18. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009 137 : 1250 1260.
19. Lugering A, Schmidt M, Lugering N, et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001 121 : 1145 1157. (Pubitemid 33022095)
20. Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000 59 : 323 389.
21. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003 17 : 1273 1281. (Pubitemid 36693728)